Protein kinase D isoforms: new targets for therapy in invasive breast cancers?

References

• Bastea LI, Doppler H, Balogun B, Storz P. Protein kinase D1 maintains the epithelial phenotype by inducing a DNA-bound, inactive SNAI1 transcriptional repressor complex. PLoS One 7(1), e30459 (2012).
   Google Scholar
• Du C, Zhang C, Hassan S, Biswas MH, Balaji KC. Protein kinase D1 suppresses epithelial-to-mesenchymal transition through phosphorylation of snail. Cancer Res. 70(20), 7810–7819 (2010).
   PubMed Web of Science ®Google Scholar
• Eiseler T, Doppler H, Yan IK, Goodison S, Storz P. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res. 11(1), R13 (2009).
   PubMedGoogle Scholar
• Chen J, Lu L, Feng Y et al. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Lett. 300(1), 48–56 (2011).
   PubMedGoogle Scholar
• Hao Q, McKenzie R, Gan H, Tang H. Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells. Anticancer Res. 33(2), 393–399 (2013).
   PubMedGoogle Scholar
• Azoitei N, Pusapati GV, Kleger A et al. Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. Gut 59(10), 1316–1330 (2010).
   PubMedGoogle Scholar
• Chen J, Deng F, Singh SV, Wang QJ. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res. 68(10), 3844–3853 (2008).
   PubMedGoogle Scholar
• Jaggi M, Rao PS, Smith DJ et al. E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer. Cancer Res. 65(2), 483–492 (2005).
   PubMed Web of Science ®Google Scholar
• Kim M, Jang HR, Kim JH et al. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis 29(3), 629–637 (2008).
   PubMedGoogle Scholar
• Zou Z, Zeng F, Xu W et al. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-kappaB- and HDAC1-mediated expression and activation of uPA. J. Cell Sci. 125(Pt 20), 4800–4811 (2012).
   PubMedGoogle Scholar
• Eiseler T, Doppler H, Yan IK, Kitatani K, Mizuno K, Storz P. Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. Nat. Cell Biol. 11(5), 545–556 (2009).
   PubMed Web of Science ®Google Scholar
• Peterburs P, Heering J, Link G, Pfizenmaier K, Olayioye MA, Hausser A. Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like. Cancer Res. 69(14), 5634–5638 (2009).
   PubMedGoogle Scholar
• Doppler H, Bastea LI, Eiseler T, Storz P. Neuregulin mediates F-actin-driven cell migration through inhibition of protein kinase D1 via Rac1 protein. J. Biol. Chem. 288(1), 455–465 (2013).
   PubMedGoogle Scholar
• Dunn M, Sinha P, Campbell R et al. Co-expression of neuregulins 1, 2, 3 and 4 in human breast cancer. J. Pathol. 203(2), 672–680 (2004).
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Kunnumakkara AB, Ochi N et al. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo. Mol. Cancer Ther. 9(5), 1136–1146 (2010).
   PubMed Web of Science ®Google Scholar
• Evans IM, Bagherzadeh A, Charles M et al. Characterization of the biological effects of a novel protein kinase D inhibitor in endothelial cells. Biochem. J. 429(3), 565–572 (2010).
   PubMedGoogle Scholar
• George KM, Frantz MC, Bravo-Altamirano K et al. Design, synthesis, and biological evaluation of PKD inhibitors. Pharmaceutics 3(2), 186–228 (2011).
   PubMedGoogle Scholar
• Sharlow ER, Giridhar KV, LaValle CR et al. Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone. J. Biol. Chem. 283(48), 33516–33526 (2008).
   PubMed Web of Science ®Google Scholar
• Gamber GG, Meredith E, Zhu Q et al. 3,5-diarylazoles as novel and selective inhibitors of protein kinase D. Bioorg. Med. Chem. Lett. 21(5), 1447–1451 (2011).
   PubMedGoogle Scholar
• Meredith EL, Ardayfio O, Beattie K et al. Identification of orally available naphthyridine protein kinase D inhibitors. J. Med. Chem. 53(15), 5400–5421 (2010).
   PubMed Web of Science ®Google Scholar
• Lavalle CR, Bravo-Altamirano K, Giridhar KV et al. Novel protein kinase D inhibitors cause potent arrest in prostate cancer cell growth and motility. BMC Chem. Biol. 10, 5 (2010).
   PubMedGoogle Scholar
• Janssens K, De Kimpe L, Balsamo M et al. Characterization of EVL-I as a protein kinase D substrate. Cell. Signal. 21(2), 282–292 (2009).
   PubMedGoogle Scholar
• Liang G, Gonzales FA, Jones PA, Orntoft TF, Thykjaer T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2´-deoxycytidine. Cancer Res. 62(4), 961–966 (2002).
   PubMed Web of Science ®Google Scholar
• Yang AS, Estecio MR, Garcia-Manero G, Kantarjian HM, Issa JP. Comment on “Chromosomal instability and tumors promoted by DNA hypomethylation” and “Induction of tumors in nice by genomic hypomethylation”. Science 302(5648), 1153; author reply 1153 (2003).
   Google Scholar
• Sundram V, Chauhan SC, Ebeling M, Jaggi M. Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS ONE 7(4), e35368 (2012).
   PubMedGoogle Scholar
• Yallapu MM, Othman SF, Curtis ET et al. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int. J. Nanomed. 7, 1761–1779 (2012).
   PubMed Web of Science ®Google Scholar
• Gschwendt M, Kittstein W, Johannes FJ. Differential effects of suramin on protein kinase C isoenzymes. A novel tool for discriminating protein kinase C activities. FEBS Lett. 421(2), 165–168 (1998).
   PubMedGoogle Scholar
• Gradishar WJ, Soff G, Liu J et al. A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. Oncology 58(4), 324–333 (2000).
   PubMed Web of Science ®Google Scholar
• Lustberg MB, Pant S, Ruppert AS et al. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother. Pharmacol. 70(1), 49–56 (2012).
   PubMed Web of Science ®Google Scholar